Loading...
Daratumumab induces CD38 internalization and impairs myeloma cell adhesion
Daratumumab (Dara), a human immunoglobulin G1 kappa (IgG1κ) monoclonal anti-CD38 antibody, has been approved by the U.S. Food and Drug Administration for the treatment of relapsed multiple myeloma (MM) as a single agent as well as in combination with immunomodulatory drugs (IMiDs) and proteasome inh...
Na minha lista:
| Udgivet i: | Oncoimmunology |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Taylor & Francis
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6169590/ https://ncbi.nlm.nih.gov/pubmed/30288349 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2018.1486948 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|